The study, led by Henry Omar Herrera of Case Western Reserve University together with colleagues at University Hospitals Cleveland Medical Center and Albert Einstein College of Medicine, set out to answer a deceptively simple question. When Hispanic or Latino patients are diagnosed with psoriasis, what is their subsequent risk of developing new-onset metabolic conditions such as type 2 diabetes, hypertension, dyslipidemia, obesity-related disorders, and metabolic syndrome? The question matters because psoriasis is already recognized as an independent risk factor for metabolic disease in the general population, but the vast majority of the evidence base has been built on cohorts of European descent.

The biological rationale for the psoriasis-metabolism connection is well established. Psoriasis is driven by a sustained activation of the immune system, particularly T cells and inflammatory signaling molecules such as tumor necrosis factor alpha, interleukin-17, and interleukin-23. These cytokines do not confine their effects to the skin. They circulate systemically, promoting insulin resistance in muscle and liver tissue, altering lipid metabolism, and encouraging the low-grade vascular inflammation that underlies atherosclerosis. Over months and years, this chronic inflammatory state can tip patients toward the metabolic syndrome cluster of abdominal obesity, elevated triglycerides, low HDL cholesterol, high blood pressure, and impaired fasting glucose.

Hispanic and Latino populations in the United States carry a distinct baseline metabolic profile that makes this interaction especially consequential. National surveillance data cited by the authors show that Hispanic Americans experience higher rates of diabetes and several of its complications compared with non-Hispanic white Americans. Large epidemiological surveys, including the landmark JAMA analysis of diabetes prevalence by race and ethnicity from 2011 to 2016, have documented that the burden of diagnosed and undiagnosed diabetes is disproportionately heavy in this community. Layering the systemic inflammation of psoriasis on top of that elevated baseline risk creates a scenario in which even a modest additional inflammatory push could translate into a meaningful increase in new metabolic diagnoses.

Yet, as the authors and prior reviewers have noted, Hispanic and Latino patients with psoriatic disease have historically been a blind spot in the literature. A comprehensive review of psoriatic disease in the US Latino population published in the American Journal of Clinical Dermatology highlighted how little controlled data exist on disease presentation, treatment response, and comorbidity trajectories in this group. Dermatology registries and biologic trials tend to enroll predominantly white participants, which means that risk estimates derived from those datasets may simply not apply to other populations. Genetic ancestry, patterns of adipose tissue distribution, dietary and occupational factors, access to care, and differences in how aggressively comorbidities are screened for can all shift the relationship between skin inflammation and metabolic outcomes.

The retrospective cohort design of the new analysis reflects both the practicality and the limitations of studying these questions with real-world medical records. Rather than randomizing patients to interventions, the researchers looked backward through clinical data, identifying Hispanic or Latino patients with a diagnosis of psoriasis vulgaris and tracking whether they went on to receive new diagnoses of metabolic comorbidities during follow-up. Retrospective cohorts of this kind are powerful for generating incidence estimates and hypothesis-generating risk signals in populations that are rarely captured in prospective trials, but they depend on the completeness and accuracy of the underlying records, and they can be vulnerable to confounding by factors such as body mass index, medication use, and healthcare utilization patterns.

Why does this matter clinically? Dermatologists are increasingly viewed as the first line of defense against the systemic consequences of psoriasis. A patient who presents with plaques on the elbows and scalp is not just a cosmetic or comfort concern; that patient carries a quantifiably elevated lifetime risk of myocardial infarction, stroke, and diabetes. Guidelines from several dermatology societies now recommend that patients with moderate to severe psoriasis undergo periodic screening for metabolic syndrome components, including blood pressure, fasting glucose or hemoglobin A1c, and lipid panels. If Hispanic and Latino patients face a higher trajectory of new-onset metabolic disease after a psoriasis diagnosis, then screening intensity, lifestyle counseling, and early referral to primary care or endocrinology may need to be calibrated differently for this population.

The study also arrives at a moment when the demographics of psoriasis in the United States are shifting. Hispanic Americans represent a large and rapidly growing share of the national population, and psoriasis affects an estimated three percent of US adults overall. Simple arithmetic dictates that the absolute number of Hispanic and Latino individuals living with psoriatic disease will continue to climb. If the comorbidity burden in this group is systematically underestimated, health systems will be caught unprepared for a wave of cardiovascular and diabetic complications that could have been anticipated and, in part, prevented. Health disparities research of this type is therefore not merely academic; it is a matter of resource allocation, screening policy, and ultimately lives saved.

There are also important mechanistic questions raised by population-specific risk research. Adiposity patterns differ across ancestral groups, with some populations showing greater visceral fat deposition at the same body mass index, and visceral fat is a particularly potent source of the inflammatory adipokines that synergize with psoriasis-related cytokines. Genetic variants influencing both immune signaling and lipid metabolism vary in frequency across populations. Socioeconomic factors, including food environments, occupational stress, and barriers to consistent healthcare, further modulate the observed risk. Disentangling these strands requires exactly the kind of targeted cohort work that the Cleveland and Bronx-based team has begun, and it argues for larger, multi-center, prospective studies with granular data on ancestry, disease severity measured by body surface area or PASI scores, and longitudinal metabolic laboratory values.

For now, the practical message for clinicians and patients is clear. Psoriasis in Hispanic and Latino patients should prompt the same vigilance toward metabolic health that the field has learned to apply in other populations, and quite possibly more. Patients should be aware that their skin condition is connected to their heart and metabolic health, and that controlling systemic inflammation, maintaining a healthy weight, staying physically active, and keeping up with metabolic screening are all part of managing psoriasis in the twenty-first century. As the evidence base grows more inclusive, the hope is that risk prediction and preventive care will finally serve every population equally, rather than only those who have historically filled the clinical trials.

Subject of Research: Risk of new-onset metabolic comorbidities in Hispanic or Latino patients with psoriasis vulgaris

Article Title: Risk of new-onset metabolic comorbidities in hispanic or latino patients with psoriasis vulgaris: a retrospective cohort analysis

Article References: Herrera, H. O., Nolasco, B., Sánchez-Feliciano, A., & Bordeaux, J. (2026). Risk of new-onset metabolic comorbidities in hispanic or latino patients with psoriasis vulgaris: a retrospective cohort analysis. Archives of Dermatological Research, 318(1), Article 512. https://doi.org/10.1007/s00403-026-04971-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04971-3

Keywords: psoriasis, psoriasis vulgaris, Hispanic health, Latino health, metabolic syndrome, type 2 diabetes, cardiovascular risk, dermatology, health disparities, retrospective cohort, chronic inflammation, comorbidities

The research team, led by Evelyn Arana-Chicas of Rutgers Cancer Institute, conducted virtual focus groups with nineteen Hispanic adults aged 50 to 77, all current or former smokers with at least a 20 pack-year history, meaning they had smoked at least a pack a day for two decades. The participants, whose average age was 60.3 years and whose average smoking exposure was 30.6 pack-years, were recruited through the patient portal of a New Jersey health system. Two of the three sessions were conducted entirely in Spanish, reflecting the fact that 68.4 percent of participants primarily spoke Spanish, and most traced their origins to South America. The discussions were structured around the Cultural Appropriateness Framework, a well-established model that examines how cultural values, beliefs, and communication preferences should shape the design of health interventions, and the transcripts were analyzed using rapid qualitative analysis following the PARRQA rigor standards.

The first and perhaps most sobering theme was how little participants knew about lung cancer screening. Many reported that despite decades of smoking, no healthcare provider had ever mentioned the low-dose CT scan that can detect lung cancer at a curable stage. Several learned about screening only through their own internet research. Equally concerning, participants said that when screening was discussed, clinicians presented the benefits while omitting the potential downsides, leaving them unaware that screening can produce false positives, incidental findings, or overdiagnosis, the detection of slow-growing tumors that might never have caused harm. The technical vocabulary of screening also created confusion. One Spanish-speaking participant interpreted the phrase “until you are no longer eligible” as a veiled message about money, while an English-speaking participant asked pointedly what a five-year survival statistic actually means for an individual patient.

The second theme centered on communication style, and the participants’ preferences were unambiguous. They wanted information delivered in clear, plain language, free of jargon like “overdiagnosis” and “incidental findings,” and they wanted it delivered with warmth. “It sounds very complicated, and it needs to be something everyone can understand,” one Spanish-speaking participant said of the term incidental findings. Another warned that verbosity itself erodes confidence: “I think ‘direct’ is the best. That’s important because when they start talking too much, people start distrusting.” Others described wanting a genuine face-to-face conversation in which the clinician lays out the options and, in the words of one participant, “gives me the power to make the decision.” These preferences echo the Hispanic cultural values of personalismo and simpatía, which emphasize personal relationships, trust, respect, and positive interpersonal connection in health encounters.

The third theme exposed a delicate psychological fault line: fear. Participants worried that heavily statistical or alarmist risk messaging could trigger anxiety and fatalism, the belief that a cancer diagnosis is a death sentence regardless of action. One English-speaking participant captured the translation problem of risk framing vividly: “In my [Latin American] country, you tell somebody they got a 90 percent chance of living, they’re hearing 10 percent chance of dying.” Fear of hearing a cancer diagnosis emerged as a genuine barrier that could keep people away from screening altogether, yet several participants also articulated the counterargument themselves, noting that early detection found in time is precisely what makes the frightening scan worthwhile. The participants favored balanced communication that acknowledged risks honestly while emphasizing prevention, reassurance, and the power of acting early, and they reacted negatively to language perceived as judgmental, coercive, or directive about their smoking.

The fourth theme surprised even seasoned health communication researchers: visual design matters enormously. Participants preferred bright, vibrant colors such as red and green in educational materials, and they wanted to see people who looked like them, Hispanic patients, families, and healthcare professionals, in the imagery. “We really like color. Color is we are very colorful,” one Spanish-speaking participant explained. Another was blunt about the alienating effect of generic materials: “The people in the pictures don’t look Hispanic. To me, they don’t represent us. I would identify more if I saw people who look like us.” Participants also preferred realistic photographs over cartoons or abstract graphics, viewing them as more credible for a topic as serious as cancer. These so-called peripheral elements, often treated as cosmetic afterthoughts in intervention design, functioned instead as signals that the information was truly meant for the community receiving it.

The context for this work is a stark and quantified disparity. Low-dose CT screening, validated by the National Lung Screening Trial as reducing lung cancer mortality compared with chest radiography, is recommended annually by the US Preventive Services Task Force for high-risk adults. But only about one in four eligible Americans is up to date with screening, with state-level rates ranging from 13 to 38 percent, and Hispanic adults fall disproportionately on the losing end. Under the 2021 criteria, 28.5 percent of Hispanic adults are screening-eligible compared with 35.8 percent of non-Hispanic White adults, partly because Hispanic adults who smoke tend to accumulate fewer pack-years. Even among those who qualify, uptake trails significantly. Hispanic individuals also face documented barriers including language obstacles, smoking-related stigma, cancer fatalism, mistrust of the healthcare system, and limited access to care.

What makes the study more than a catalog of barriers is its intended target: the TELESCOPE intervention, a telehealth program that pairs shared decision-making coaching with patient navigation to guide eligible patients through screening conversations in primary care. Because Medicare requires a shared decision-making visit before reimbursing a first screening scan, the quality of that conversation is not a nicety but a structural gatekeeper. The new findings give the Rutgers team a specific adaptation roadmap, extending beyond simple translation to communication tone, risk framing, and visual identity, while preserving the core evidence-based components of coaching and navigation. The framework analysis also showed that the themes did not map neatly onto single domains; limited awareness cut across everything, and communication preferences intersected the linguistic, evidential, and sociocultural dimensions simultaneously, suggesting that piecemeal adaptation will not be enough.

The researchers acknowledge limitations: the participants came from a single New Jersey academic center, were recruited through electronic health records and a digital portal, and met virtually, all of which may underrepresent people least connected to healthcare or technology. Group audio recordings also made it hard to attribute individual quotations reliably. Yet the diversity of national origins, language preferences, and acculturation levels among the nineteen participants lends the findings real breadth. The broader lesson radiates well beyond lung cancer. As screening programs across medicine confront populations they have historically underserved, this study argues that trust is built not only by what medicine says but by how it says it, in the vocabulary patients use, in images that reflect their faces, in a tone that respects their fears without exploiting them, and in the quiet dignity of being given a real choice.

Subject of Research: Cultural adaptation of lung cancer screening shared decision-making and navigation for Hispanic adults

Article Title: Informing the cultural adaptation of a lung cancer screening shared decision-making and navigation intervention for Hispanic adults: a qualitative study

Article References: Informing the cultural adaptation of a lung cancer screening shared decision-making and navigation intervention for Hispanic adults: a qualitative study. (n.d.). https://doi.org/10.1007/s10552-026-02257-7

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02257-7

Keywords: lung cancer screening, Hispanic health, shared decision-making, cultural adaptation, health disparities, low-dose CT, patient navigation, telehealth, cancer fatalism, qualitative research, health communication, TELESCOPE intervention